{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:24:50Z","timestamp":1783441490931,"version":"3.54.6"},"reference-count":73,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,4,1]]},"abstract":"<jats:p>Although treatment of children and adolescents who have disorders of growth and adolescent development with aromatase inhibitors is increasingly common, data for or against their use are extremely limited. Precocious puberty, short stature, and gynecomastia are conditions for which inhibition of the enzyme aromatase might prove beneficial to reduce clinical signs of estrogenization and\/or estrogen-mediated skeletal maturation. In this report, we summarize the published data regarding the use of aromatase inhibitors in these conditions, and review known and potential benefits, safety concerns, and shortcomings of the available information.<\/jats:p>","DOI":"10.1542\/peds.2007-2081","type":"journal-article","created":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T20:25:58Z","timestamp":1207081558000},"page":"e975-e983","source":"Crossref","is-referenced-by-count":70,"title":["Use of Aromatase Inhibitors in Children and Adolescents With Disorders of Growth and Adolescent Development"],"prefix":"10.1542","volume":"121","author":[{"given":"Dorothy I.","family":"Shulman","sequence":"first","affiliation":[{"name":"All Children's Hospital, St Petersburg, and Department of Pediatrics, University of South Florida College of Medicine, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary L.","family":"Francis","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Virginia Commonwealth University, Richmond, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Palmert","sequence":"additional","affiliation":[{"name":"Rainbow Babies and Children's Hospital and Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica A.","family":"Eugster","sequence":"additional","affiliation":[{"name":"Riley Hospital for Children, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Lawson Wilkins Pediatric Endocrine Society Drug and Therapeutics Committee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2008,4,1]]},"reference":[{"key":"2021120902142618200_R1","doi-asserted-by":"crossref","unstructured":"Brodie AM, Banks PK, Inkster SE, Dowsett M, Coombes RC. Aromatase inhibitors and hormone dependent cancers. J Steroid Biochem Mol Biol.\u20081990;37(3):327\u2013333","DOI":"10.1016\/0960-0760(90)90481-Y"},{"key":"2021120902142618200_R2","doi-asserted-by":"crossref","unstructured":"Bulun SE, Zeitoun K, Takayama K, et al. Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis. Endocr Relat Cancer.\u20081999;6(2):293\u2013301","DOI":"10.1677\/erc.0.0060293"},{"key":"2021120902142618200_R3","doi-asserted-by":"crossref","unstructured":"Miller WR, Jackson J. The therapeutic potential of aromatase inhibitors. Expert Opin Investig Drugs.\u20082003;12(3):337\u2013351","DOI":"10.1517\/13543784.12.3.337"},{"key":"2021120902142618200_R4","doi-asserted-by":"crossref","unstructured":"Dunkel L. Use of aromatase inhibitors to increase final height. Mol Cell Endocrinol.\u20082006;254\u2013255:207\u2013216","DOI":"10.1016\/j.mce.2006.04.031"},{"key":"2021120902142618200_R5","doi-asserted-by":"crossref","unstructured":"Plourde PV, Reiter EO, Jou H-C, et al. Members of the AsraZeneca Gynecomastia Study. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab.\u20082004;89(9):4428\u20134433","DOI":"10.1210\/jc.2004-0082"},{"key":"2021120902142618200_R6","doi-asserted-by":"crossref","unstructured":"Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med.\u20081994;331(16):1056\u20131061","DOI":"10.1056\/NEJM199410203311604"},{"key":"2021120902142618200_R7","doi-asserted-by":"crossref","unstructured":"Morishima A, Grumbach M, Simpson E, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab.\u20081995;80(12):3689\u20133698","DOI":"10.1210\/jcem.80.12.8530621"},{"key":"2021120902142618200_R8","doi-asserted-by":"crossref","unstructured":"Cash R, Brough AJ, Cohen MN, Satoh PS. Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial. J Clin Endocrinol Metab.\u20081967;27(9):1239\u20131248","DOI":"10.1210\/jcem-27-9-1239"},{"key":"2021120902142618200_R9","doi-asserted-by":"crossref","unstructured":"Thompson EA Jr, Siiteri PK. The involvement of human placental microsomal cytochrome P-450 in aromatization. J Biol Chem.\u20081974;249(17):5373\u20135378","DOI":"10.1016\/S0021-9258(20)79736-X"},{"key":"2021120902142618200_R10","doi-asserted-by":"crossref","unstructured":"Geisler J, Lonning PE. Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res.\u20082005;11(8):2809\u20132821","DOI":"10.1158\/1078-0432.CCR-04-2187"},{"key":"2021120902142618200_R11","doi-asserted-by":"crossref","unstructured":"Cavalli A, Bisi A, Bertucci C, et al. Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem.\u20082005;48(23):7282\u20137289","DOI":"10.1021\/jm058042r"},{"key":"2021120902142618200_R12","doi-asserted-by":"crossref","unstructured":"Numazawa M, Handa W, Hasegawa C, Takahashi M. Structure-activity relationships of 2 alpha-substituted androstenedione analogs as aromatase inhibitors and their aromatization reactions. J Steroid Biochem Mol Biol.\u20082005;97(4):353\u2013359","DOI":"10.1016\/j.jsbmb.2005.06.029"},{"key":"2021120902142618200_R13","doi-asserted-by":"crossref","unstructured":"Cavalieri E, Chakravarti D, Guttenplan J, et al. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochem Biophys Acta.\u20082006;1766(1):63\u201378","DOI":"10.1016\/j.bbcan.2006.03.001"},{"key":"2021120902142618200_R14","doi-asserted-by":"crossref","unstructured":"Chen S, Zhang F, Sherman MA, et al. Structure-function studies of aromatase and its inhibitors: a progress report. J Steroid Biochem Mol Biol.\u20082003;86(3\u20135):231\u2013237","DOI":"10.1016\/S0960-0760(03)00361-3"},{"key":"2021120902142618200_R15","doi-asserted-by":"crossref","unstructured":"Saberi MR, Vinh TK, Yee SW, Griffiths BJ, Evans PJ, Simons C. CYP19 (aromatase) 1-[(benzofuran-2-yl)(phenylmethyl) pyridine, -imidazole, and -triazole inhibitors: synthesis and biological evaluation. J Med Chem.\u20082006;49(3):1016\u20131022","DOI":"10.1021\/jm0508282"},{"key":"2021120902142618200_R16","unstructured":"Walgreens.com. Drug Information. Available at www.walgreens.com\/library\/finddrug\/druginfosearch.jsp. Accessed February 4, 2008."},{"key":"2021120902142618200_R17","doi-asserted-by":"crossref","unstructured":"Eugster EA. Aromatase inhibitors in precocious puberty: rationale and experience to date. Treat Endocrinol.\u20082004;3(3):141\u2013151","DOI":"10.2165\/00024677-200403030-00002"},{"key":"2021120902142618200_R18","doi-asserted-by":"crossref","unstructured":"Geisler J, Lonning PE. Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations. J Steroid Biochem Mol Biol.\u20082005;95(1\u20135):75\u201381","DOI":"10.1016\/j.jsbmb.2005.04.015"},{"key":"2021120902142618200_R19","doi-asserted-by":"crossref","unstructured":"Laue L, Kenigsberg D, Pescovitz OH, et al. Treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med.\u20081989;320(8):496\u2013502","DOI":"10.1056\/NEJM198902233200805"},{"key":"2021120902142618200_R20","doi-asserted-by":"crossref","unstructured":"Laue L, Jones J, Barnes KM, Cutler GB Jr. Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin. J Clin Endocrinol Metab.\u20081993;76(1):151\u2013155","DOI":"10.1210\/jcem.76.1.8421081"},{"key":"2021120902142618200_R21","doi-asserted-by":"crossref","unstructured":"Leschek EW, Jones J, Barnes KM, Hill SC, Cutler GB Jr. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab.\u20081999;84(1):175\u2013178","DOI":"10.1210\/jcem.84.1.5413"},{"key":"2021120902142618200_R22","unstructured":"Reiter EO, Narjavaara E. Testotoxicosis: current viewpoint. Pediatr Endocrinol Rev.\u20082005;3(2):77\u201386"},{"key":"2021120902142618200_R23","doi-asserted-by":"crossref","unstructured":"Kreher NC, Pescovitz OH, Delameter P, Tiulpakov A, Hochberg Z. Treatment of familial male-limited precocious puberty with bicalutamide and anastrazole. J Pediatr.\u20082006;149(3):416\u2013420","DOI":"10.1016\/j.jpeds.2006.04.027"},{"key":"2021120902142618200_R24","doi-asserted-by":"crossref","unstructured":"Feuillan PP, Foster CM, Pescovitz OH, et al. Treatment of precocious in the McCune-Albright syndrome with the aromatase inhibitor testolactone. N Engl J Med.\u20081986;315(18):1115\u20131119","DOI":"10.1056\/NEJM198610303151802"},{"key":"2021120902142618200_R25","doi-asserted-by":"crossref","unstructured":"Feuillan PP, Jones J, Cutler GB Jr. Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab.\u20081993;77(3):647\u2013651","DOI":"10.1210\/jcem.77.3.8370686"},{"key":"2021120902142618200_R26","doi-asserted-by":"crossref","unstructured":"Nunez SB, Calis K, Cutler GB Jr, Jones J, Feuillan PP. Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab.\u20082003;88(12):5730\u20135733","DOI":"10.1210\/jc.2003-030864"},{"key":"2021120902142618200_R27","unstructured":"Roth C, Freiberg C, Zappel H, Albers N. Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab.\u20082002;15(suppl 3):945\u2013948"},{"key":"2021120902142618200_R28","unstructured":"Kunz GJ, Mao CS Gottschalk ME. Anastrozole Use During Precocious Puberty in McCune-Albright Syndrome [abstract]. Presented at: 85th annual meeting of the Endocrine Society; June 19\u201320, 2003; Philadelphia, PA"},{"key":"2021120902142618200_R29","unstructured":"Mieszczak J, Lowe E, Plourde P, Eugster EA. Anastrozole treatment of precocious puberty in girls with McCune-Albright syndrome [abstract 7517.7]. Presented at: annual meeting of the Pediatric Academic Society, May 3\u20138, 2007; Toronto, Ontario, Canada"},{"key":"2021120902142618200_R30","doi-asserted-by":"crossref","unstructured":"Feuillan P, Calis K, Hill S, Shawker T, Robey PG, Collins MT. Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study. J Clin Endocrinol Metab.\u20082007;92(6):2100\u20132106","DOI":"10.1210\/jc.2006-2350"},{"key":"2021120902142618200_R31","unstructured":"Albers N, Jorgens S, Deiss D, Hauffa BP. McCune-Albright syndrome: the German experience. J Pediatr Endocrinol Metab.\u20082002;15(suppl 3):897\u2013901"},{"key":"2021120902142618200_R32","doi-asserted-by":"crossref","unstructured":"Bonfig W, Bechtold S, Schmidt H, Knorr D, Schwarz HP. Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty. J Clin Endocrinol Metab.\u20082007;92(5):1635\u20131639","DOI":"10.1210\/jc.2006-2109"},{"key":"2021120902142618200_R33","doi-asserted-by":"crossref","unstructured":"Silva IN, Kater CE, Cunha CF, Viana MB. Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Arch Dis Child.\u20081997;77(3):214\u2013218","DOI":"10.1136\/adc.77.3.214"},{"key":"2021120902142618200_R34","doi-asserted-by":"crossref","unstructured":"Eugster EA, Dimeglio LA, Wright JC, Freidenberg GR, Seshadri R, Pescovitz OH. Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis. J Pediatr.\u20082001;138(1):26\u201332","DOI":"10.1067\/mpd.2001.110527"},{"key":"2021120902142618200_R35","doi-asserted-by":"crossref","unstructured":"Merke DP, Keil MF, Jones JV, Fields J, Hill S, Cutler GB Jr. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab.\u20082000;85(3):1114\u20131120","DOI":"10.1210\/jcem.85.3.6462"},{"key":"2021120902142618200_R36","doi-asserted-by":"crossref","unstructured":"Braunstein G. Gynecomastia. N Engl J Med.\u20081993;328(7):490\u2013495","DOI":"10.1056\/NEJM199302183280708"},{"key":"2021120902142618200_R37","doi-asserted-by":"crossref","unstructured":"Harlan WR, Grillo GP, Cornoni-Huntley J, Leaverton PE. Secondary sex characteristics of boys 12 to 17 years of age: the U.S. Health Examination Survey. J Pediatr.\u20081979;95(2):293\u2013297","DOI":"10.1016\/S0022-3476(79)80677-0"},{"key":"2021120902142618200_R38","doi-asserted-by":"crossref","unstructured":"Williams M. Gynecomastia: Its incidence, recognition and host characterization in 447 autopsy cases. Am J Med.\u20081963;34:103\u2013112","DOI":"10.1016\/0002-9343(63)90044-5"},{"key":"2021120902142618200_R39","doi-asserted-by":"crossref","unstructured":"Nicolis GL, Modlinger RS, Gabrilove JL. A study of the histopathology of human gynecomastia. J Clin Endocrinol Metab.\u20081971;32(2):173\u2013178","DOI":"10.1210\/jcem-32-2-173"},{"key":"2021120902142618200_R40","doi-asserted-by":"crossref","unstructured":"Bannayan GA, Hajdu SI. Gynecomastia: clinicopathologic study of 351 cases. Am J Clin Pathol.\u20081972;57(4):431\u2013437","DOI":"10.1093\/ajcp\/57.4.431"},{"key":"2021120902142618200_R41","doi-asserted-by":"crossref","unstructured":"Nydick M, Bustos J, Dale JH Jr, Rawson RW. Gynecomastia in adolescent boys. JAMA.\u20081961;178:449\u2013454","DOI":"10.1001\/jama.1961.03040440001001"},{"key":"2021120902142618200_R42","doi-asserted-by":"crossref","unstructured":"Plourde P, Julin H, Santner S. Clomiphene in the treatment of adolescent gynaecomastia. Am J Dis Child.\u20081983;137(11):1080\u20131082","DOI":"10.1001\/archpedi.1983.02140370040013"},{"key":"2021120902142618200_R43","doi-asserted-by":"crossref","unstructured":"Ko\u0308nig R, Schonberger W, Neumann P, Benes P, Grimm W. Treatment of marked gyecomastia in puberty with tamoxifen [in German]. Klin Padiatr.\u20081987;199(6):389\u2013391","DOI":"10.1055\/s-2008-1026828"},{"key":"2021120902142618200_R44","doi-asserted-by":"crossref","unstructured":"Eberle A, Sparrow J, Keenan B. Treatment of persistent pubertal gynecomastia with dihydrotestosterone heptanoate. J Pediatr.\u20081986;109(1):144\u2013149","DOI":"10.1016\/S0022-3476(86)80596-0"},{"key":"2021120902142618200_R45","doi-asserted-by":"crossref","unstructured":"Beck W, Stubbe P. Endocrinological studies of the hypothalamo-pituitary gonadal axis during danazol treatment in pubertal boys with marked gynecomastia. Horm Metab Res.\u20081982;14(12):653\u2013657","DOI":"10.1055\/s-2007-1019110"},{"key":"2021120902142618200_R46","doi-asserted-by":"crossref","unstructured":"Zachmann M, Eiholzer U, Muritano M, Werder EA, Manella B. Treatment of pubertal gynaecomastia with testolactone. Acta Endocrinol.\u20081986;279(suppl):218\u2013226","DOI":"10.1530\/acta.0.112S218"},{"key":"2021120902142618200_R47","doi-asserted-by":"crossref","unstructured":"Riepe FG, Baus I, Wiest S, Krone N, Sippell WG, Partsch CJ. Treatment of pubertal gynecomastia with the specific aromatase inhibitor anastrozole. Horm Res.\u20082004;62(3):113\u2013118","DOI":"10.1159\/000079882"},{"key":"2021120902142618200_R48","doi-asserted-by":"crossref","unstructured":"Klein KO, Baron J, Colli MJ, McDonnell DP, Cutler GB Jr. Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay. J Clin Invest.\u20081994;94(6):2475\u20132480","DOI":"10.1172\/JCI117616"},{"key":"2021120902142618200_R49","doi-asserted-by":"crossref","unstructured":"Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol.\u20082005;23(4):808\u2013815","DOI":"10.1200\/JCO.2005.12.013"},{"key":"2021120902142618200_R50","doi-asserted-by":"crossref","unstructured":"Lefevre H, Bouvattier C, Lahlou N, Adamsbaum C, Bougneres P, Carel J-C. Prepubertal gynecomastia in Peutz-Jeghers syndrome: incomplete penetrance in a familial case and management with an aromatase inhibitor. Eur J Endocrinol.\u20082006;154(2):221\u2013227","DOI":"10.1530\/eje.1.02085"},{"key":"2021120902142618200_R51","doi-asserted-by":"crossref","unstructured":"Kara C, Kutlu AO, Tosun MS, Apaydin S, Senel F. Sertoli cell tumor causing prepubertal gynecomastia in a boy with Peutz-Jeghers syndrome: the outcome of 1 year treatment with the aromatase inhibitor testolactone. Horm Res.\u20082005;63(5):252\u2013256","DOI":"10.1159\/000086325"},{"key":"2021120902142618200_R52","doi-asserted-by":"crossref","unstructured":"Shozu M, Sebastian S, Takayama K, et al. Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. N Engl J Med.\u20082003;348(19):1855\u20131865","DOI":"10.1056\/NEJMoa021559"},{"key":"2021120902142618200_R53","doi-asserted-by":"crossref","unstructured":"Stratakis CA, Vottero A, Brodie A, et al. The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription. J Clin Endocrinol Metab.\u20081998;83(4):1348\u20131357","DOI":"10.1210\/jc.83.4.1348"},{"key":"2021120902142618200_R54","doi-asserted-by":"crossref","unstructured":"Leschek EW, Rose SR, Yanovski JA, et al. Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab.\u20082004;89(7):3140\u20133148","DOI":"10.1210\/jc.2003-031457"},{"key":"2021120902142618200_R55","doi-asserted-by":"crossref","unstructured":"Wit JM, Balen HV, Kamp GA, Oostdijk W. Benefit of postponing normal puberty for improving final height. Eur J Endocrinol.\u20082004;151(suppl 1):S41\u2013S45","DOI":"10.1530\/eje.0.151s041"},{"key":"2021120902142618200_R56","doi-asserted-by":"crossref","unstructured":"Pasquino AM, Pucarelli I, Roggini M, Segni M. Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone. J Clin Endocrinol Metab.\u20082000;85(2):619\u2013622","DOI":"10.1210\/jcem.85.2.6387"},{"key":"2021120902142618200_R57","doi-asserted-by":"crossref","unstructured":"Mauras N, Hayes V, Welch S, et al. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab.\u20081998;83(6):1886\u20131892","DOI":"10.1210\/jc.83.6.1886"},{"key":"2021120902142618200_R58","doi-asserted-by":"crossref","unstructured":"Boot AM, Demuinck Keizer-Schrama SM, Pols HA, Drenning EP, Drop SL. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with precocious and early puberty. J Clin Endocrinol Metab.\u20081998;83(2):370\u2013373","DOI":"10.1210\/jc.83.2.370"},{"key":"2021120902142618200_R59","doi-asserted-by":"crossref","unstructured":"Yanovski JA, Rose SR, Municchi G, et al. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med.\u20082003;348(10):908\u2013917","DOI":"10.1056\/NEJMoa013555"},{"key":"2021120902142618200_R60","doi-asserted-by":"crossref","unstructured":"Faglia G, Arosio M, Porretti S. Delayed closure of epiphyseal cartilages induced by the aromatase inhibitor anastrozole: would it help short children grow up?J Endocrinol Invest.\u20082000;23(11):721\u2013723","DOI":"10.1007\/BF03345059"},{"key":"2021120902142618200_R61","doi-asserted-by":"crossref","unstructured":"Wickman S, Sipila I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet.\u20082001;357(9270):1743\u20131748","DOI":"10.1016\/S0140-6736(00)04895-9"},{"key":"2021120902142618200_R62","doi-asserted-by":"crossref","unstructured":"Mauras N, Welch S, Rini A, Klein KO. An open label 12-month pilot trial on the effects of the aromatase inhibitor anastrozole in growth hormone (GH)-treated GH deficient adolescent boys. J Pediatr Endocrinol Metab.\u20082004;17(12):1597\u20131606","DOI":"10.1515\/JPEM.2004.17.12.1597"},{"key":"2021120902142618200_R63","doi-asserted-by":"crossref","unstructured":"Karmazin A, Moore WV, Popovic J, Jacobson JD. The effect of letrozole on bone age progression, predicted adult height, and adrenal gland function. J Pediatr Endocrinol Metab.\u20082005;18(3):285\u2013293","DOI":"10.1515\/JPEM.2005.18.3.285"},{"key":"2021120902142618200_R64","doi-asserted-by":"crossref","unstructured":"Hero M, Norjavaara E, Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab.\u20082005;90(12):6396\u20136402","DOI":"10.1210\/jc.2005-1392"},{"key":"2021120902142618200_R65","doi-asserted-by":"crossref","unstructured":"Hero M, Wickman S, Dunkel L. Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin Endocrinol (Oxf).\u20082006;64(5):510\u2013513","DOI":"10.1111\/j.1365-2265.2006.02499.x"},{"key":"2021120902142618200_R66","unstructured":"Cernich J, Jacobson JD, Moore WV, Popovic J. Use of aromatase inhibitors in children with short stature. Pediatr Endocrinol Rev.\u20082004;2(1):2\u20137"},{"key":"2021120902142618200_R67","unstructured":"Turpin AL, Popovic J, Karmazin A, Moore WV, Jacobson JD. Aromatase inhibitor may delay skeletal maturation and improve final adult height in females [abstract]. 86th Annual Meeting of the Endocrine Society, New Orleans, LA, June 16\u201319, 2004"},{"key":"2021120902142618200_R68","unstructured":"Mauras N, Gonzalez de Pijem L, Hsiang H, et al. Placebo controlled, double blind, randomized trial of the safety and efficacy of Arimidex in delaying epiphyseal fusion in growth hormone (GH) deficient males in puberty: preliminary results [abstract]. 88th Annual Meeting of the Endocrine Society, Boston, MA, June 24\u201328, 2006"},{"key":"2021120902142618200_R69","unstructured":"Front H, Lampit M, Hochberg Z. Aromatase inhibition therapy in pubertal short boys [abstract]. ESPE\/LWPES Seventh Joint Meeting, Lyon, France, September 21\u201324, 2005"},{"key":"2021120902142618200_R70","doi-asserted-by":"crossref","unstructured":"Carreau S, Delalande C, Silandre D, Bourquiba S, Lambard S. Aromatase and estrogen receptors in male reproduction. Mol Cell Endocrinol.\u20082006;246(1\u20132):65\u201368","DOI":"10.1016\/j.mce.2005.11.021"},{"key":"2021120902142618200_R71","doi-asserted-by":"crossref","unstructured":"Simpson ER. Genetic mutations resulting in estrogen insufficiency in the male. Mol Cell Endocrinol.\u20081998;145(1\u20132):55\u201359","DOI":"10.1016\/S0303-7207(98)00169-5"},{"key":"2021120902142618200_R72","doi-asserted-by":"crossref","unstructured":"Mauras N, Bell J, Snow BG, Winslow KL. Sperm analysis in growth hormone-deficient adolescents previously treated with an aromatase inhibitor: comparison with normal controls. Fertil Steril.\u20082005;84(1):239\u2013242","DOI":"10.1016\/j.fertnstert.2005.02.012"},{"key":"2021120902142618200_R73","doi-asserted-by":"crossref","unstructured":"Hero M, Ankarberg-Lindgren C, Taskinen MR, Dunkel L. Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition. Eur J Endocrinol.\u20082006;155(3):453\u2013460","DOI":"10.1530\/eje.1.02226"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/4\/e975\/1123008\/zpe0040800e975.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/4\/e975\/1123008\/zpe0040800e975.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T10:18:44Z","timestamp":1639045124000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/121\/4\/e975\/70904\/Use-of-Aromatase-Inhibitors-in-Children-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,1]]},"references-count":73,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2008,4,1]]},"published-print":{"date-parts":[[2008,4,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2007-2081","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,1]]}}}